Clinical Trials on Stomatitis, Herpetic

Total 1924 results

Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function

Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States
Intercept Pharmaceuticals

Completed

Hepatic Impairment Trial of Obeticholic Acid

Hepatic Impairment

United States
Dong-A Pharmaceutical Co., Ltd.

Completed

A Pharmacokinetic Study of Udenafil in Adult Subjects With or Without Impaired Hepatic Function (udenafil)

Hepatic Impairment

Korea, Republic of
AstraZeneca
PRA Health Sciences

Completed

Pharmacokinetics, Safety & Tolerability of ZD4054 (Zibotentan) in Subjects With Normal, Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

Czech Republic
Guangdong Provincial Hospital of Traditional Chinese...

Recruiting

A Study of Laparoscopic Right Hemicolectomy Using the Caudal-to-cranial Approach (LRHCTC-1)

Ascending Colon Cancer | Ileocaecal Valve Carcinoma | Cancer Flexure Hepatic | Adenocarcinoma of Hepatic Flexure (Diagnosis)

China
University of Edinburgh
NHS Lothian

Not yet recruiting

Biomarkers in Liver Failure

Acute on Chronic Hepatic Failure | Acute Liver Failure | Acute Liver Injury
Bayer

Completed

Study of Copanlisib in Hepatic or Renal Impairment

Hepatic Insufficiency, Renal Insufficiency

Germany, Romania
AstraZeneca

Recruiting

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone

Hepatic Impairment

United States
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
PPD Development, L.P.

Recruiting

DZD9008 PK Study in Hepatic Impairment Subjects

Hepatic Impairment

United States
Takeda

Recruiting

A Study About Fazirsiran in People With and Without Liver Problems

Hepatic Impairment

Hungary, Slovakia
Janssen Research & Development, LLC

Recruiting

A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function

Hepatic Impairment

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment

United States
Mirati Therapeutics Inc.

Completed

A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib

Hepatic Impairment

United States
Corcept Therapeutics

Completed

A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

Hepatic Impairment

United States
Indiana University

Completed

Evaluation of the Efficacy of Contrast Enhanced Ultrasound Compared to MRI for Differentiation of Hepatic Lesions

Hepatic Disease

United States
VectivBio AG

Completed

A Phase 1, Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

Germany, Slovakia
Novartis Pharmaceuticals

Completed

Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

Hepatic Impairment

United States
Insmed Incorporated

Completed

A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

Hepatic Impairment

United States
Cerevel Therapeutics, LLC

Completed

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Hepatic Impairment

United States
Shionogi

Completed

A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants

Hepatic Impairment

United States
Celgene

Completed

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
AstraZeneca
Parexel

Terminated

Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment

Hepatic Impairment

United States
Portola Pharmaceuticals

Completed

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

Hepatic Impairment

United States
AbbVie

Terminated

A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
Zogenix, Inc.

Completed

Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic Impairment

Hepatic Impairment
Hutchison Medipharma Limited

Completed

Surufatinib Hepatic Impairment Study

Hepatic Impairment

United States
Kadmon, a Sanofi Company

Completed

KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States
Galectin Therapeutics Inc.

Completed

A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States
F2G Biotech GmbH

Completed

A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Bristol-Myers Squibb

Completed

A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment

Hepatic Impairment

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Hepatic Impairment

Hepatic Impairment

United States
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib

Hepatic Impairment

Germany
Daiichi Sankyo, Inc.

Completed

Study of Single-dose DS-3201b in Participants With Hepatic Impairment

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function

Hepatic Impairment

United States
Celgene

Completed

A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects

Hepatic Impairment

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Pfizer

Completed

Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States, Belgium, Czechia, Slovakia
Aragon Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function

Hepatic Impairment

United States
Ipsen

Completed

Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects

Hepatic Impairment

Moldova, Republic of, Romania
Midwestern Regional Medical Center

Terminated

Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Hepatic Injury

Cancer | Hepatic Injury

United States
Eli Lilly and Company
AstraZeneca

Withdrawn

A Study of LY3314814 in Participants With Liver Impairment

Hepatic Impairment

United States
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment

Hepatic Impairment

China
Novartis Pharmaceuticals

Completed

A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

Hepatic Impairment

Germany
Melinta Therapeutics, Inc.

Completed

Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment

Hepatic Impairment

United States
Samsung Electronics

Terminated

Evaluation of the Samsung LABGEO PT10 Hepatic Panel in a Point-of-Care Setting

Hepatic Disease

United States
FORUM Pharmaceuticals Inc
PRA Health Sciences

Completed

EVP-6124 Hepatic Impairment Study

Hepatic Impairment

Czech Republic, Poland, Slovakia
LG Life Sciences

Completed

Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers

Hepatic Impairment

Germany
Janssen Research & Development, LLC

Completed

A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function

Hepatic Impairment

United States

3

Subscribe